{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"19.4","value":"12.5"},{"comment":"\\<75% of participants experienced the event within the treatment arm. Hence, third-quartile could not be derived.","groupId":"OG001","lowerLimit":"4.2","upperLimit":"NA","value":"6.2"},{"groupId":"OG002","lowerLimit":"3.4","upperLimit":"10.4","value":"9.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"description":"DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 2.5 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 39 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG000","title":"Main Study: GSK2857916 2.5 mg/kg (Frozen Liquid)"},{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 3.4 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 32 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG001","title":"Main Study: GSK2857916 3.4 mg/kg (Frozen Liquid)"},{"description":"Participants were administered lyophilized powder (100 mg/vial in a single use vial) at a dose of 3.4 mg/kg GSK2857916 given IV for a maximum of 35 cycles (1 cycle= 21 days). Lyophilized powder was reconstituted using water for injection.","id":"OG002","title":"Main Study: GSK2857916 3.4 mg/kg (Lyophilized)"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Population. Only responders (confirmed PR or better) by Independent Review Committee were included in this analysis","reportingStatus":"POSTED","timeFrame":"Up to 186 weeks","title":"Duration of Response by Independent Review Committee (Full Analysis Population)","type":"SECONDARY","unitOfMeasure":"Months"}